



Ontario Company Announces a Significant Global Partnership in the Fight against Prostate Cancer

Profound Medical Inc. (PMI) and **Siemens Healthcare** have today entered into an agreement to partner on a global, multi-site, human safety/feasibility clinical trial initiative spanning Europe, the US, and Canada.

In Canada, 12 men die of prostate cancer every day and about 25,000 were newly diagnosed in 2009.

Glen Murray, Ontario's Minister of Research & Innovation, commented, "I lost my father to prostate cancer, and I see too many struggle with this illness. I am thrilled to see this partnership formed - the creativity, drive and entrepreneurship of companies like Profound Medical and Siemens are helping hasten the day when we can talk about prostate cancer in the past tense."

Worldwide, prostate cancer affects more than 500,000 men annually. Worryingly, many of those treated with existing methods subsequently suffer the debilitating side-effects of impotence and incontinence, and require further procedures.

Paul Chipperton, CEO of Profound Medical, stated: "We are developing a truly unique, minimally-invasive medical device for the treatment of prostate cancer, combining the already proven clinical efficacy of ultrasound thermal therapy with the unparalleled imaging capabilities of MRI."

"Siemens' global reputation for research and development excellence, coupled with the ubiquity of the Siemens Magnetom Tim MRI Systems in all our target markets, made it a natural fit to interface the two companies' technologies to provide improved speed, precision and accuracy in the treatment of prostate cancer," Chipperton added.

The companies will each bring complementary expertise in terms of hardware, software, and technical support to accelerate Profound's clinical trials.

About Profound Medical

Profound Medical Inc. (PMI) of Toronto, Canada, is a spin-out of Sunnybrook Research Institute, and is a multi-award winning medical device company developing an MRI-guided, trans-urethral procedure for the treatment of localized prostate cancer. Learn more at www.profoundmedical.com.

For more information please contact Paul Chipperton:

T: ++1 647 291 8545

E: pchipperton@profoundmedical.com

W: www.profoundmedical.com